Sodium cromoglicate — side effects, contraindications and why it does not relieve an asthma attack

LIMITED EFFECTIVENESS | NON-TOXIC

What names is the drug known by

International and pharmacopoeial names: cromoglicic acid; sodium cromoglicate — sodium cromoglicate, cromolyn sodium, disodium cromoglycate; Russian variants — sodium cromoglicate, cromoglicic acid, cromolyn. Dosage forms include solution and powder for inhalation, metered-dose nasal spray, eye drops, and an oral solution or concentrate. Common trade names include Intal, Cromohexal, Cromoglin, Cromospir, Cromoglicic Acid, Lomuzol, Lomustal, Lomudal, Intal, NasalCrom, Opticrom, Gastrocrom, Nalcrom. Different dosage forms should not be regarded as interchangeable: Gastrocrom solution is intended for oral administration and must not be used for inhalation or injection. There are virtually no widely used combination medicines in which sodium cromoglicate is the second therapeutically active component; therefore, inadvertent duplication is more likely to occur when several topical forms are used simultaneously — for example, a nasal spray, eye drops and an inhalation solution — although, because systemic absorption is low, this does not usually result in classic dose-dependent toxicity.

Why the drug is considered harmless and where the real risk begins

Sodium cromoglicate does indeed have low systemic toxicity, but its main danger in asthma is not poisoning; it is misunderstanding the purpose of the drug. It is a preventive treatment with no bronchodilator action of its own: it does not relieve established bronchospasm and should not be used instead of a fast-acting bronchodilator during an acute attack. Repeating cromoglicate inhalations while breathlessness is worsening can waste critically important time, while the inhalation itself may sometimes aggravate coughing, wheezing and bronchospasm. The maximum preventive effect may take several weeks to develop, so the absence of immediate relief is an expected property of the drug, not a reason to keep increasing the number of inhalations indefinitely.

Side effects during the first hours and days of use

Common reactions to inhaled forms are caused by local irritation of the airways: cough, throat irritation, nasal congestion, sneezing, wheezing and discomfort in the throat. With inhaled powder, transient cough was reported in approximately one in five patients, while mild wheezing occurred in about one in twenty-five. A clinically significant complication is bronchospasm occurring immediately after inhalation; in some cases it persists even after prior use of a bronchodilator and requires discontinuation of the drug. Severe paradoxical bronchospasm occurs rarely. Life-threatening reactions include anaphylaxis, angioedema and laryngeal edema with impaired breathing. Eye drops may cause temporary burning, stinging, irritation and blurred vision; nasal forms may cause burning, mucosal irritation and nosebleeds. Oral administration may cause nausea, vomiting, diarrhea, abdominal pain, rash and arthralgia.

Risks of long-term and repeated use

No confirmed cumulative hepato-, nephro-, cardio- or neurotoxicity has been established with standard use of sodium cromoglicate. The drug is barely metabolized, is poorly absorbed from the gastrointestinal tract, and the absorbed fraction is eliminated mainly unchanged in the urine and bile. Tolerance, drug dependence and a specific withdrawal syndrome are not characteristic of sodium cromoglicate. However, long-term use of topical forms can maintain irritation of the airways, nose or eyes. With ophthalmic solutions, adverse effects during use over many months may sometimes be related less to cromoglicate itself than to the preservative benzalkonium chloride, which can worsen dry eye, disrupt the tear film and damage an already vulnerable corneal surface. The main long-term risk in asthma is masking inadequate disease control and continuing a predictably weak preventive regimen instead of treatment that actually reduces the risk of severe exacerbations.

Contraindications and higher-risk groups

An absolute contraindication is hypersensitivity to sodium cromoglicate or to the excipients of the specific dosage form. The inhaled drug must not be used to treat status asthmaticus or as the sole treatment for an acute attack of breathlessness. In patients who develop marked bronchospasm after inhalation, continued use may be dangerous. The safety of the inhaled form in children under two years of age has not been adequately established. In severe impairment of kidney or liver function, the systemically absorbed fraction of the drug is eliminated more slowly, so dose reduction may be considered for the oral solution. Oral cromoglicate is not intended to prevent anaphylactic shock caused by food allergy and cannot replace epinephrine and emergency treatment in a patient with a history of anaphylaxis. Ophthalmic solutions containing benzalkonium chloride require particular caution in dry eye syndrome, corneal damage and in users of soft contact lenses.

Dangerous interactions

Few pharmacokinetically significant drug interactions have been established for sodium cromoglicate because its systemic bioavailability is low and it undergoes virtually no metabolism. No direct, confirmed dangerous interaction with alcohol, caffeine, nicotine or food has been described. However, this does not mean that an inhalation solution can be mixed directly in a nebulizer chamber with bronchodilators, glucocorticosteroids, antibiotics or other medicines: the stability, compatibility and safety of such mixtures may not have been established. Replacing a fast-acting bronchodilator with cromoglicate during an attack or independently discontinuing controller anti-inflammatory therapy is strongly inadvisable. With eye drops, other ophthalmic solutions and preservatives must also be taken into account: frequent simultaneous use of several products may increase irritation and damage to the ocular surface. The main risk from combinations in this case is not an increase in cromoglicate concentration but a therapeutic error and an incorrect sequence of administration.

Patient errors

The most dangerous mistake is using sodium cromoglicate as a rescue medication for wheezing and breathlessness. The drug does not dilate the bronchi, so repeated inhalations during an attack do not replace a bronchodilator and may further irritate the airways. Another mistake is judging effectiveness after one or several doses: the preventive effect usually develops gradually and may not reach its maximum until after two to four weeks of regular use. Common errors include irregular inhalations only when symptoms occur, missed doses, independently increasing the frequency of use, putting the oral solution into a nebulizer, mixing several medicines in the same chamber, and continuing treatment after reproducible bronchospasm. The opposite mistake is abruptly stopping regular preventive treatment after improvement: there is no toxic withdrawal syndrome, but asthma symptoms may return as the preventive effect is lost.

Overdose and poisoning

No clearly defined single toxic dose of sodium cromoglicate has been established in humans, and the approved dosage forms have extremely low systemic toxicity. In animal studies, oral doses of up to 8,000 mg/kg were not associated with fatal outcomes; prolonged inhalational exposure also failed to produce systemically toxic concentrations. For the oral form, cases of overdose have not been described in official documentation, while symptomatic observation is recommended after accidental ingestion of eye drops. There is no specific antidote. Nevertheless, repeated inhalations may cause not systemic poisoning but a rapidly developing local complication — cough, wheezing and severe bronchospasm. If breathlessness, chest tightness or hoarseness worsens after administration, or swelling of the lips, tongue, face or larynx develops, it is unsafe to wait “for the drug to start working”: this may represent paradoxical bronchospasm or anaphylaxis requiring immediate emergency treatment. If a large amount is accidentally taken orally, management is based on assessment of symptoms and supportive treatment rather than an antidote or preventive gastric lavage.

Safe integrative alternative

As the main integrative alternative to preventive sodium cromoglicate use in allergic bronchial asthma, the most substantiated option is Bronchial Asthma Type 2 based on Clerodendrum serratum. The pharmacological rationale for substitution is associated with mast-cell stabilization, reduced histamine release, and suppression of the IgE-dependent response, eosinophilic inflammation and Th2 cytokines. Experimental studies of Clerodendrum serratum demonstrate membrane-stabilizing, antihistamine, bronchospasmolytic and anti-inflammatory effects that are therapeutically similar in direction to those of cromoglicate. When asthma is accompanied by allergic rhinitis, polyvalent allergy or pronounced mucosal inflammation, Allergy Mixture Capsules, containing Andrographis paniculata, Schefflera leucantha, Murdannia loriformis and other components, may be considered. Andrographis pharmacologically complements the formula by suppressing NF-κB-dependent inflammation, eosinophilia, bronchial hyperreactivity and mucus hypersecretion; these properties have so far been confirmed mainly in preclinical models of asthma. With thick, difficult-to-expectorate sputum, an additional option may be Bolus “Asthma with Tenacious Sputum” based on Solanum trilobatum: clinical pilot studies have reported improvements in ventilatory parameters, although its effect was weaker than that of standard bronchodilators. Schefflera leucantha may be used as an additional antiallergic component. Albizia myriophylla should not be presented as a direct analogue of Albizia lebbeck or as the primary substitute for cromoglicate. None of the formulations listed above is intended to relieve an acute attack of breathlessness.

Real effectiveness of sodium cromoglicate and prescribing errors

Sodium cromoglicate can reduce allergic reactivity of the mucous membranes when used regularly for prevention because it inhibits degranulation of sensitized mast cells and the release of histamine and leukotrienes. It may be useful in allergic rhinitis, allergic conjunctivitis, certain forms of mastocytosis and mild allergic asthma, but its effect develops gradually and requires administration several times a day. The drug does not dilate the bronchi, does not relieve established bronchospasm and does not treat an acute attack. Sodium cromoglicate has a limited role in modern maintenance therapy for asthma: anti-inflammatory regimens are available that have a more predictable effect on exacerbations and disease control. The current GINA strategy considers asthma an inflammatory disease that requires effective anti-inflammatory therapy rather than preventive reliance on a drug with slow and moderate efficacy. Typical prescribing errors include using cromoglicate without confirming an allergic phenotype, using it as the sole controller medication in moderate or severe asthma, failing to check inhalation technique and failing to provide an action plan for an attack. Another error is continuing formally “safe” treatment despite persistent nighttime symptoms, limitation of physical activity and frequent need for a bronchodilator. Low toxicity does not turn insufficient effectiveness into an advantage.

Safety monitoring during treatment

Special regular laboratory monitoring of liver function, kidney function or blood parameters is usually not required with standard topical use of sodium cromoglicate. Monitoring should primarily be clinical: the frequency of daytime and nighttime symptoms, need for rescue medication, exercise tolerance, presence of cough or wheezing after inhalation, frequency of exacerbations, and peak expiratory flow or spirometry results. Worsening bronchospasm immediately after administration is a reason to discontinue the inhaled form and reassess treatment. Increasing breathlessness, inability to speak in full sentences, marked retraction of the intercostal spaces, cyanosis, confusion, a rapid fall in peak expiratory flow, and swelling of the face, lips, tongue or larynx require immediate medical attention. Such symptoms may indicate a severe exacerbation, paradoxical bronchospasm or anaphylaxis. Waiting for the preventive effect of cromoglicate in this situation worsens the prognosis because the drug has no rescue bronchodilator action.

Proper discontinuation and consequences of stopping treatment

Sodium cromoglicate does not cause a pharmacological withdrawal syndrome or physical dependence, and there is no requirement to taper the dose gradually. The drug can be stopped immediately in the event of an allergic reaction, paradoxical bronchospasm or absence of an indication for treatment. However, after long-term effective use, discontinuation should preferably be discussed with the treating specialist because mast-cell reactivity may gradually return after preventive treatment is stopped, and symptoms of allergic rhinitis, conjunctivitis or asthma may recur. This is not a toxic withdrawal reaction but the loss of the controlling effect. Cromoglicate and other anti-asthma medications should not be stopped simultaneously without assessing disease control. Switching to a herbal formula must also not leave the patient without a fast-acting medication for relief of an attack or without adequate maintenance therapy in moderate, severe or unstable asthma.

A reasonable approach to treatment

Sodium cromoglicate is justified when local prevention of an allergic reaction is required, systemic toxicological exposure should be minimal, and the patient is able to follow a frequent dosing schedule. Its benefits are most evident in allergic rhinitis, conjunctivitis and certain mild allergic conditions. In bronchial asthma, the drug has limited effectiveness and should not be regarded as complete protection against an attack. In mild and stable allergic disease, Bronchial Asthma Type 2 based on Clerodendrum serratum may be a potential integrative alternative. For more extensive allergic inflammation, Allergy Mixture Capsules may be used, while in the presence of viscous sputum an additional product containing Solanum trilobatum may be considered. Complete substitution is acceptable only when the condition is stable and symptoms are controlled. With frequent attacks, nighttime breathlessness, reduced lung function or a need for an emergency bronchodilator, herbal therapy may only supplement maintenance treatment rather than replace it through unsupervised discontinuation.

If you have questions about the topic of this article, you can ask a clinical pharmacologist in the comments or make an appointment using this link: https://asiabiopharm.com/konsultaciii/